Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors

被引：0
作者：
Anthony W. Tolcher
Razelle Kurzrock
Vincente Valero
Rene Gonzalez
Rebecca S. Heist
Antoinette R. Tan
Julie Means-Powell
Theresa L. Werner
Carlos Becerra
Chenxi Wang
Cathrine Leonowens
Shanker Kalyana-Sundaram
Joseph F. Kleha
Jennifer Gauvin
Anthony M. D’Amelio
Catherine Ellis
Nageatte Ibrahim
Li Yan
机构：
[1] South Texas Accelerated Research Therapeutics,Division of Hematology and Oncology, Moores Cancer Center
[2] University of California,Division of Cancer Medicine, Department of Breast Medical Oncology
[3] The University of Texas MD Anderson Cancer Center,Division of Medical Oncology, Melanoma Research Clinics
[4] University of Colorado Cancer Center,Division of Medical Oncology, Department of Medicine, Huntsman Cancer Institute
[5] Massachusetts General Hospital,Texas Oncology
[6] Rutgers Cancer Institute of New Jersey,Levine Cancer Institute
[7] Sarah Cannon Research Institute,undefined
[8] University of Utah,undefined
[9] US Oncology-Baylor University Medical Center,undefined
[10] GlaxoSmithKline,undefined
[11] Novartis Pharmaceuticals Corporation,undefined
[12] NEXT Oncology,undefined
[13] Atrium Health,undefined
[14] Cathrine Leonowens Consulting LLC,undefined
[15] Array Biopharma,undefined
[16] Merck & Co,undefined
[17] Brii Biosciences Limited,undefined
[18] Texas Oncology,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2020年 / 85卷
关键词：
AKT inhibitor; -wild type melanoma; MEK inhibitor; Trametinib; Triple-negative breast cancer; Uprosertib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：673 / 683
页数：10
相关论文
共 153 条
[11]  
Lim SY(2015)Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma Cancer Chemother Pharmacol 75 183-3800
[12]  
Menzies AM(2012)Improved survival with MEK inhibition in BRAF-mutated melanoma N Engl J Med 367 107-1835
[13]  
Rizos H(2013)Characterization of a chemical affinity probe targeting Akt kinases J Proteome Res 12 3792-781
[14]  
Hu Y(2014)Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor PLoS ONE 9 e100880-738
[15]  
Gu Y(2015)Dose-finding quantitative 18F-FDG PET imaging study with the oral pan-AKT inhibitor GSK2141795 in patients with gynecological malignancies J Nucl Med 56 1828-436
[16]  
Wang H(2012)Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial Lancet Oncol 13 773-247
[17]  
Huang Y(2011)Safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of the oral AKT inhibitor GSK2141795 (GSK795) in a phase I first-in-human study J Clin Oncol 29 3003-862
[18]  
Zou YM(2015)A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors Clin Cancer Res 21 730-728
[19]  
Liu Y(2007)A parallel phase I/II clinical trial design for combination therapies Biometrics 63 429-1605
[20]  
Sheikh MS(2009)New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 228-12
12345678910